Marc Odrich
No más puestos en curso
Fortuna: 2 M $ al 30/04/2024
Perfil
Marc Odrich is currently the Chief Medical Officer & Director at TearSolutions, Inc., the Director at CXL Ophthalmics LLC, the Chief Medical Officer at LENZ Therapeutics, Inc., and an Associate Professor at the University of Virginia.
He previously worked as the Medical Director at VISX, Inc. Dr. Odrich holds a doctorate degree from Columbia University College of Physicians & Surgeons.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0.39% | 21/03/2024 | 99 599 ( 0.39% ) | 2 M $ | 30/04/2024 |
Cargos activos de Marc Odrich
| Empresas | Cargo | Inicio |
|---|---|---|
TearSolutions, Inc.
 TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | - |
CXL Ophthalmics LLC
 CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Director/Miembro de la Junta | - |
| University of Virginia | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Marc Odrich.
| Empresas | Cargo | Fin |
|---|---|---|
| VISX, Inc. | Director Técnico/Científico/I+D | - |
Formación de Marc Odrich.
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
TearSolutions, Inc.
TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Health Technology |
| VISX, Inc. | |
CXL Ophthalmics LLC
CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Health Services |
- Bolsa de valores
- Insiders
- Marc Odrich